It has been a mystery to scientists for years: being well vaccinated against hepatitis B, but still being able to become infected with the HBV virus. CyTuVax from Maastricht is currently testing a vaccine that reduces the so-called non-response effect. In other words: the risk of infection is further reduced. In November, the last of more than 130 test subjects will receive an injection in the study, CyTuVax expects to publish the results in early 2019. An earlier study already gave positive results; 90% of the test subjects were protected against the virus after vaccination with the new product. The company would like to achieve this result again: “We are confident that the data from the first phase of the study will be reconfirmed. In addition, we hope for a more comprehensive understanding of the effectiveness and safety of our product in a larger group of non-responders. We aim to provide at least 85% of non-responders with a vaccine,” explains Paul van den Brekel, one of the company’s founders.

Read all the articles in our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!

Become a member!

On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.

About the author

Author profile picture Milan Lenters is a writer and editor. Through IO, he got to know his native city Eindhoven in a different way and sometimes looks with amazement at the many stories that lie ahead.